contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


sprint-bioscience-presents-preclinical-data-from-the-disa-program-at-research-conference

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Sprint Bioscience is a research company. The company develops pharmaceutical candidates that alone or in combination with other pharmaceuticals can fight cancer. The company has a project portfolio focused on attacking parts of cancer cell processes. The company's business model is based on developing projects parallel in the preclinical phase to subsequently enter into licensing agreements with the global pharmaceutical industry. The company was founded in 2009 and is headquartered in Huddinge.

Sprint Bioscience

Sprint Bioscience AB (publ) today announces that previously unpublished results from the company's DISA program will be presented at the conference STING & TLR-Targeting Therapies Summit in ...

<div class="mfn-preamble"><p><strong>Sprint Bioscience AB (publ) today announces that previously unpublished results from the company's DISA program will be presented at the conference STING &amp; TLR-Targeting Therapies Summit in Boston, USA, May 9 - 11, 2023.</strong></p></div><div class="mfn-body"><p>The results show that the TREX1 inhibitors developed by Sprint Bioscience within the DISA program led to the activation of immune signaling in cancer cells from different types of tumors and that they have an effect that surpasses other inhibitors that are under development by other companies. The results have increased the understanding of how the TREX1 protein acts in cancer cells and how it enables these cells to escape the immune system.<br>"The results increase the mechanistic understanding and provide further support that inhibition of TREX1 has the opportunity to develop into a treatment option for patients with various types of cancer. We are proud to be able to present these data to the foremost researchers in the field," says Martin Andersson, CSO at Sprint Bioscience.<br>STING &amp; TLR-Targeting Therapies Summit is a specialized conference with participants from companies and academic groups that focus on research and drug development with the aim of blocking the ability of cancer cells to escape the immune response in the tumor. The conference covers everything from basic research to clinical trials and many present previously completely unpublished information.<br>The poster ‘Fragment-based drug development of TREX1 inhibitors’ is presented by Yasmin Yu, Ph.D., Senior Scientist, Sprint Bioscience.</p><p><strong class="mfn-heading-1">For further information, kindly contact:</strong><br>&nbsp;<br>Martin Andersson, CSO, Sprint Bioscience <br>Tel: 08-411 44 55<br>Epost: <a rel="noopener" href="mailto:martin.andersson@sprintbioscience.com">martin.andersson@sprintbioscience.com</a><br>&nbsp;</p></div><div class="mfn-footer mfn-about mfn-b8edf498b215"><p><strong class="mfn-heading-1">About Sprint Bioscience AB (publ)</strong></p><hr><p>Sprint Bioscience develops small-molecule <em>first-in-class</em> drug programs with a focus on oncology. Using fragment-based drug discovery, the company develops drug programs in a time- and resource-efficient way and then license them to global pharma companies during the preclinical phase. The company has successfully entered into several license agreements amounting to a potential value of USD 507 million in milestone payments as well as income from royalties on sales. The company is headquartered in Stockholm with laboratories in Huddinge. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and is traded under the short name SPRINT. Further information is available on the company's website; <a rel="noopener" href="http://www.sprintbioscience.com.">www.sprintbioscience.com</a>. <br>Certified Advisor is FNCA Sweden AB; <a rel="noopener" href="http://www.fnca.se.">www.fnca.se</a>.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/01b35f16-482a-4d94-af32-0d97b69e4db9/sprint-bioscience-presents-preclinical-data-from-the-disa-program-at-research-conference.pdf" class="mfn-generated mfn-primary">Sprint Bioscience presents preclinical data from the DISA program at research conference</a></p></div>

Sprint Bioscience presents preclinical data from the DISA program at research conference

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!